Xinyu Zong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Xinyu Zong has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Dengyun Nie
Taizhou People’s Hospital Affiliated to Nanjing University of Chinese Medicine, Taizhou 225300, China
1 shared publication Ji Zhou
Nanjing Med Univ, Sch Basic Med Sci, Dept Physiol, Nanjing, Jiangsu, Peoples R China
1 shared publicationJiaofeng Zhou
Nanjing Med Univ, Sch Basic Med Sci, Dept Physiol, Nanjing, Jiangsu, Peoples R China
1 shared publication- Jie Mei
The First Clinical Medicine College, Nanjing Medical University, Nanjing, China
1 shared publication - Junli Ding
Department of Oncology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, China
1 shared publication - Junxing Huang
Taizhou People’s Hospital Affiliated to Nanjing University of Chinese Medicine, Taizhou 225300, China
1 shared publication
Latest Publications
- 21 November 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 144, 113637
Lovastatin-mediated pharmacological inhibition of Formin protein DIAPH1 suppresses tumor immune escape and boosts immunotherapy response
- 21 November 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 144, 113637
Lovastatin-mediated pharmacological inhibition of Formin protein DIAPH1 suppresses tumor immune escape and boosts immunotherapy response
- Open Access
- 5 September 2022
- Published by MDPI AG in Biomolecules
- Vol. 12 (9) , 1239
Research Progress on Nanoparticles-Based CRISPR/Cas9 System for Targeted Therapy of Tumors
Cancer is a genetic mutation disease that seriously endangers the health and life of all human beings. As one of the most amazing academic achievements in the past decade, CRISPR/Cas9 technology has been sought after by many researchers due to its powerful gene editing capability. CRISPR/Cas9 technology shows great potential in oncology, and has become one of the most promising technologies for cancer genome-editing therapeutics. However, its efficiency and the safety issues of in vivo gene editing severely limit its widespread application. Therefore, developing a suitable delivery method for the CRISPR/Cas9 system is an urgent problem to be solved at present. Rapid advances in nanomedicine suggest nanoparticles could be a viable option. In this review, we summarize the latest research on the potential use of nanoparticle-based CRISPR/Cas9 systems in cancer therapeutics, in order to further their clinical application. We hope that this review will provide a novel insight into the CRISPR/Cas9 system and offer guidance for nanocarrier designs that will enable its use in cancer clinical applications.
- 5 September 2022
- Published by MDPI AG in Biomolecules
- Vol. 12 (9) , 1239
Open AccessResearch Progress on Nanoparticles-Based CRISPR/Cas9 System for Targeted Therapy of Tumors
Cancer is a genetic mutation disease that seriously endangers the health and life of all human beings. As one of the most amazing academic achievements in the past decade, CRISPR/Cas9 technology has been sought after by many researchers due to its powerful gene editing capability. CRISPR/Cas9 technology shows great potential in oncology, and has become one of the most promising technologies for cancer genome-editing therapeutics. However, its efficiency and the safety issues of in vivo gene editing severely limit its widespread application. Therefore, developing a suitable delivery method for the CRISPR/Cas9 system is an urgent problem to be solved at present. Rapid advances in nanomedicine suggest nanoparticles could be a viable option. In this review, we summarize the latest research on the potential use of nanoparticle-based CRISPR/Cas9 systems in cancer therapeutics, in order to further their clinical application. We hope that this review will provide a novel insight into the CRISPR/Cas9 system and offer guidance for nanocarrier designs that will enable its use in cancer clinical applications.